Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Preliminary Findings

Journal of Cardiac Failure

Volumn 15, Issue 10, 2009, Pages 856-863

  Fasullo, Sergio ^a   Cannizzaro, Sergio ^a   Maringhini, Giorgio ^a   Ganci, Filippo ^a   Giambanco, Francesco ^a   Vitale, Giuseppe ^a   Pinto, Vito ^a   Migliore, Giuseppe ^a   Torres, Daniele ^b   Sarullo, Filippo M ^c   Paterna, Salvatore ^d   Di Pasquale, Pietro ^a  

^a Ospedale GF Ingrassia   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Buccheri La Ferla Hospital   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ejection fraction; end systolic volume; ivabradine; metoprolol; STEMI

Indexed keywords

CREATINE KINASE; IVABRADINE; METOPROLOL SUCCINATE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART MUSCLE REPERFUSION; HEART RATE; HOSPITAL READMISSION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STENT THROMBOSIS; SUDDEN DEATH; TREATMENT DURATION; VISUAL DISORDER;

AGED; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PILOT PROJECTS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70450224100     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.05.013     Document Type: Article

References (45)

1. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110 (2004) 588-636
2. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320 (1989) 618-627
3. Roberts R., Rogers W.J., Mueller H.S., Lambrew C.T., Diver D.J., Smith H.C., et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83 (1991) 422-437
4. Pfisterer M., Cox J.L., Granger C.B., Brener S.J., Naylor C.D., Califf R.M., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 32 (1998) 634-640
5. Di Pasquale P., Paterna S., Bucca V., Marenghini G., and Magatti M. Effects of administration of captopril, metoprolol, and captopril-metoprolol combination as adjuvant therapy during thrombolysis in acute myocardial infarction. Int J Cardiol 46 (1994) 107-112
6. Dyer A.R., Persky V., Stamler J., et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112 (1980) 736-749
7. Kannel W.B., Kannel C., Paffenbarger R.S., et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113 (1987) 1489-1494
8. Gillum R.F., Makuc D.M., and Feldman J.J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 121 (1991) 172-177
9. Mensink G.B., and Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 18 (1997) 1404-1410
10. Kristal-Boneh E., Silber H., Harari G., et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality: eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 1 (2000) 116-124
11. Reunanen A., Karjalainen J., Ristola P., et al. Heart rate and mortality. J Intern Med 247 (2000) 231-239
12. Fujiura Y., Adachi H., Tsuruta M., et al. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol 54 (2001) 495-500
13. Bois P., Bescond J., Renaudon B., and Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118 (1996) 1051-1057
14. Camm A.J., and Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4 (2003) 83-89
15. DiFrancesco D., and Camm J.A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
16. Custodis F., Baumhäkel M., Schlimmer N., List F., Gensch C., Böhm M., et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117 (2008) 2377-2387
17. Maczewski M., and Mackiewicz U. Effect of metoprolol and Ivabradine on left ventricular remodelling and Ca+ handling in the post-infarction rat heart. Cardiovasc Res 79 (2008) 42-51
18. Langenbach M.R., Schmitz-Spanke S., Brockert M., Schepan M., Pomblum V.J., Gams E., et al. Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg (Torino) 47 (2006) 719-725
19. Heusch G., Skyschally A., Gres P., van Caster P., Schilawa D., and Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 29 (2008) 2265-2275
20. Skyschally A., Schulz R., and Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz 33 (2008) 88-100
21. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantification of left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2 (1989) 358-367
22. Oh J.K., Appleton C.P., Hatle L.K., et al. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 10 (1997) 246-270
23. Benetos A., Thomas F., Bean K., et al. Resting heart rate in older people: a predictor of survival to 85. J Am Geriatr Soc 51 (2003) 284-285
24. Manz M., Reuter M., Lauck G., Omran H., and Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003) 149-155
25. Borer J.S., Fox K., Jaillon P., and Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
26. De Ferrari G.M., Mazzuero A., Agnesina L., Bertoletti A., Lettino M., Campana C., Schwartz P.J., et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10 (2008) 550-555
27. Hjalmarson A., Gilpin E.A., Kjekshus J., et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65 (1990) 547-553
28. Singh N. Diabetes, heart rate, and mortality. J Cardiovasc Pharmacol Ther 7 (2002) 117-129
29. Gundersen T., Grottum P., Pedersen T., et al. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol 58 (1989) 20-24
30. Kjekshus J.K. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57 (1986) 43F-49F
31. Kjekshus J. Heart rate reduction: a mechanism of benefit?. Eur Heart J 8 Suppl L (1987) 115-122
32. Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol 21 12 Suppl. II (1998) II3-7
33. Lechat P., Hulot J.-S., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103 (2001) 1428-1433
34. Guth B.D., Heusch G., Seitelberger R., et al. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischaemia in conscious dogs. Circ Res 60 (1987) 738-746
35. Simonsen S., Ihlen H., and Kjekshus J.K. Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand 213 (1983) 393-398
36. Purcell H. Heart rate as a therapeutic target in ischaemic heart disease. Eur Hear J Suppl 1 Suppl H (1999) H58-H63
37. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrar R., and on behalf of the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 807-816
38. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., and Ferrar R. on behalf of the BEAUTIFUL investigators Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372 (2008) 817-821
39. Rao K., Fisher M.L., Robinson S., Shorofsky S., and Gottlied S.S. Effect of chronic changes in heart rate on congestive heart failure. J Cardiac Fail 13 (2007) 269-274
40. Colin P., Ghaleh B., Monnet X., et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308 (2004) 236-240
41. Colin P., Ghaleh B., Monnet X., et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284 (2003) H676-H682
42. Colin P., Ghaleh B., Hittinger L., et al. Differential effects of heart rate reduction and [beta]-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282 (2002) H672-H679
43. Vaillant F., Timour Q., Manati W., Belhani D., Bui-Xuan B., et al. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmcol 52 (2008) 548-554
44. Ibanez B., Prat-González S., Speidl W.S., Vilahur G., Pinero A., Cimmino G., et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage. Analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115 (2007) 2909-2916
45. Wikstrand J., Hjalmarson A., Waagstein F., et al., MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40 (2002) 491-498